156 completed, 26 unknown, 18 terminated, 13 recruiting. 234 Phase 2, 34 Phase 1, 33 Phase 3.
Follow Type 2 Diabetes: new trials by email Literature Review of Type 2 Diabetes trials Research Report on Type 2 Diabetes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High - Type 2 Diabetes, High Blood Pressure | Phase 1 / Phase 2 | Withdrawn | ARKAY Therapeutics | 2026-12-10 | 2026-07-16 | |
| Relacorilant in Patients With Poorly Controlled Type 2 Diabetes and Autonomous Cortisol Secretion Relacorilant - Type 2 Diabetes, Hypercortisolism | Phase 1 / Phase 2 | Not yet recruiting | The University of Texas Health Science Center at San Antonio | 34 | 2026-12-01 | 2026-11-09 |
| A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus SAL0150 dose 1, SAL0150 dose 2, SAL0150 dose 3 - Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes | Phase 2 | Not yet recruiting | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 364 | 2026-10-30 | 2026-11-06 |
| Effects of Different Fish Oil Types on Type 2 Diabetes Risk Factors in High-Risk Adults Fish Oil, Corn oil control - Type 2 Diabetes, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance) | Phase 2 | Recruiting | May Faraj, PDt, PhD | 84 | 2026-10-05 | 2026-10-08 |
| A Study of HRS-4729 Injection in Participants With Type 2 Diabetes HRS-4729 Injection, Mazdutide, Placebo - Type 2 Diabetes | Phase 2 | Not yet recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 240 | 2026-10-01 | 2026-09-28 |
| Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus PG-102(MG12), Dulaglutide - Type 2 Diabetes | Phase 2 | Not yet recruiting | ProGen. Co., Ltd. | 60 | 2026-10-01 | 2026-07-01 |
| Exercise and Intranasal Insulin in Type 2 Diabetes Intranasal Insulin, Intranasal Placebo, High Intensity Exercise - Type 2 Diabetes, Insulin Sensitivity/Resistance | Phase 2 / Phase 3 | Recruiting | Rutgers, The State University of New Jersey | 60 | 2026-08-03 | 2026-06-30 |
| A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D GUB-UCN2, Placebo - Obesity, Type 2 Diabetes | Phase 1 / Phase 2 | Recruiting | Gubra A/S | 188 | 2026-07-27 | 2026-09-10 |
| A1Cantus vs. Placebo A1C Drink, Placebo drink - Type 2 Diabetes | Phase 2 | Not yet recruiting | University of California, Riverside | 50 | 2026-06-15 | 2026-05-18 |
| Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes, China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes - Type 2 Diabetes | Phase 2 / Phase 3 | Active not recruiting | Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair | 600 | 2026-06-15 | 2026-08-27 |
| Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors SGLT-2 inhibitor (Sotagliflozin), Insulin withdrawal test (IWT) - Type 1 Diabetes, Type 2 Diabetes | Phase 2 | Not yet recruiting | AdventHealth Translational Research Institute | 75 | 2026-06-01 | 2026-02-19 |
| Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy icovamenib 100 mg, Placebo - Type 2 Diabetes | Phase 2 | Recruiting | Biomea Fusion Inc. | 60 | 2026-04-30 | 2026-10-20 |
| Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets icovamenib 100mg, Placebo - Type 2 Diabetes | Phase 2 | Active not recruiting | Biomea Fusion Inc. | 64 | 2026-03-27 | 2026-08-28 |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) clofutriben, Placebo - Type 2 Diabetes, Cortisol Excess | Phase 2 | Recruiting | Sparrow Pharmaceuticals | 1500 | 2025-11-29 | 2026-10-06 |
| A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease Guominkang Granules, Standard Antihypertensive, Antidiabetic, and Lipid-Lowering Regimen - Diabetic Kidney Disease (DKD), Type 2 Diabetes | Phase 2 | Active not recruiting | Beijing University of Chinese Medicine | 15 | 2025-10-20 | 2026-11-02 |
| The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes Liraglutide Pen Injector, Saline Injections - Type 1 Diabetes, Type 2 Diabetes | Phase 2 | Recruiting | Mayo Clinic | 60 | 2025-10-03 | 2026-10-19 |
| A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes LY3549492, Placebo - Obesity, Overweight | Phase 2 | Terminated | Eli Lilly and Company | 1 | 2025-06-19 | 2026-08-31 |
| Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus Semaglutide (1 Mg Dose), Sitagliptin (DPP4 inhibitor) - Type 2 Diabetes | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 240 | 2025-06-01 | 2026-01-28 |
| Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study Kerendia (Finerenone, BAY94-8862), Placebo - Cardiovascular Autonomic Neuropathy, Type 2 Diabetes | Phase 2 | Recruiting | Peter Rossing | 100 | 2025-05-02 | 2025-05-25 |
| Novel Chinese Medicine Formula for Diabetes JM-LD, JM-HD, Placebo - Type 2 Diabetes | Phase 2 | Not yet recruiting | Chinese University of Hong Kong | 162 | 2025-05-01 | 2025-05-18 |
Showing 20 of 234. Sign in to see all of them.
Diabetes Mellitus, Type 2 (234) · Diabetes Mellitus (37) · Insulin Resistance (29) · Obesity (26) · Overweight (12) · Renal Insufficiency, Chronic (9) · Inflammation (6) · Non-alcoholic Fatty Liver Disease (6) · Cardiovascular Diseases (5) · Diabetic Nephropathies (5) · Metabolic Syndrome (5) · Motor Activity (5) · Hypertension (4) · Prediabetic State (4) · Dyslipidemias (3)
Nutritional and Metabolic Diseases (234) · Endocrine System Diseases (232) · Glucose Metabolism Disorders (232) · Metabolic Diseases (231) · Diabetes Mellitus (197) · Pathological Conditions, Signs and Symptoms (42) · Hyperinsulinism (33) · Signs and Symptoms (31) · Nutrition Disorders (27) · Overnutrition (27) · Body Weight (26) · Pathologic Processes (18) · Female Urogenital Diseases and Pregnancy Complications (17) · Urogenital Diseases (17) · Female Urogenital Diseases (16)
Metformin (17) · dulaglutide (9) · Pioglitazone (8) · Liraglutide (5) · dapagliflozin (5) · Cholecalciferol (4) · Exenatide (4) · Sitagliptin Phosphate (4) · semaglutide (4) · Insulin (3) · Insulin Glargine (3) · Tirzepatide (3) · mazdutide (3) · tesaglitazar (3) · AZD1656 (2)
Eli Lilly and Company (10) · AstraZeneca (9) · Jiangsu HengRui Medicine Co., Ltd. (7) · Gan and Lee Pharmaceuticals, USA (4) · University of Aarhus (4) · University of Toronto (4) · DiObex (3) · Hanoi Medical University (3) · Ionis Pharmaceuticals, Inc. (3) · Kyowa Kirin Co., Ltd. (3) · Mario Negri Institute for Pharmacological Research (3) · Medical University of Vienna (3) · University of British Columbia (3) · ActivX Biosciences, Inc. (2) · Biomea Fusion Inc. (2)
United States (91) · China (42) · Canada (28) · Denmark (11) · Mexico (9) · Poland (9) · Germany (8) · Japan (8) · Italy (7) · Puerto Rico (7) · United Kingdom (7) · Australia (6) · Argentina (5) · France (5) · Austria (4)
Andre Marette, PhD (2) · Changyu Pan, M.D. (2) · Graydon Meneilly, MD (2) · Helene Jacques, PhD (2) · K Segal, PhD (2) · Kazuoki Kondo, MD (2) · Liyuan Zhao, Ph.D (2) · Piero Ruggenenti, MD (2) · Sanjay Bhanot (2) · Adnan Agha, FRCP (1) · Adrian Di Bisceglie, MD, FACP, FAASLD (1)
PMID 26894924, PMID 27461213, PMID 30765435, PMID 10801260, PMID 11007769, PMID 11756340, PMID 11960602, PMID 12086935, PMID 12681026, PMID 12815141, PMID 1400291, PMID 14685229, PMID 15220351, PMID 16155076, PMID 16218959, PMID 16308421, PMID 16940989, PMID 16953201, PMID 17026483, PMID 17166340, PMID 17199724, PMID 17283239, PMID 17379048, PMID 17429083, PMID 17560332, PMID 17682120, PMID 17686832, PMID 17848609, PMID 17916599, PMID 17941868, PMID 17987126, PMID 18235087, PMID 18473688, PMID 18663165, PMID 18852398, PMID 1900072, PMID 19114612, PMID 19132850, PMID 19528367, PMID 19538242, PMID 19632975, PMID 19698154, PMID 19918015, PMID 20003208, PMID 20004680, PMID 20047620, PMID 20067626, PMID 20231565, PMID 20370378, PMID 20380657
2023 (4), 2005 (1), 2009 (1), 2014 (1), 2015 (1), 2016 (1), 2025 (1), KL2RR024151 (1), R01DK041973 (1), R01DK061644 (1), R01DK076092 (1), R01DK089557 (1), R01DK147509 (1), R21DK123582 (1), R21NR018349 (1)